首页> 美国卫生研究院文献>Cost Effectiveness and Resource Allocation : C/E >Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

【2h】

Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

机译：在英国有症状的慢性阻塞性肺疾病患者中梅克立铵/维兰特罗联合治疗与噻托溴铵单药治疗相比具有成本效益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundThe cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific economic model based on a chronic obstructive pulmonary disease (COPD) disease-progression model.

机译：背景使用基于慢性阻塞性肺疾病（COPD）疾病发展模型的UMEC / VI治疗特定经济模型，评估了溴乌梅地溴铵-维兰特罗（UMEC / VI）与噻托溴铵单药治疗的成本效益。

著录项

期刊名称 Cost Effectiveness and Resource Allocation : C/E
作者
Yogesh Suresh Punekar; Graeme Roberts; Afisi Ismaila; Martin O’Leary;
展开▼
作者单位

展开▼
年(卷),期 2015(13),-1
年度 2015
页码 22
总页数 8
原文格式 PDF
正文语种
中图分类
关键词
Chronic obstructive pulmonary disease Cost-effectiveness Tiotropium Umeclidinium/vilanterol;

机译：慢性阻塞性肺疾病;成本效益;噻托溴铵;Umeclidinium /维兰特罗;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK [J] . Yogesh Suresh Punekar, Graeme Roberts, Afisi Ismaila, Cost Effectiveness Resource Allocation . 2015,第1期

机译：Umeclidinium / Vilanterol组合治疗的成本效益与英国慢性阻塞性肺病症状患者的脱噻唑类单药治疗相比
2. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials [J] . Marc Decramer, Antonio Anzueto, Edward Kerwin, The lancet. Respiratory medicine. . 2014,第6期

机译：umeclidinium联合维兰特罗与噻托溴铵，vilanterol或umeclidinium单一疗法在慢性阻塞性肺疾病患者中超过24周的疗效和安全性：两项多中心，盲法，随机对照试验的结果
3. Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective [J] . Dhvani Shah, Maurice Driessen, Nancy Risebrough, Cost Effectiveness Resource Allocation . 2018,第1期

机译：Umeclidinium的成本效果与噻托溴铵和糖酮作为慢性阻塞性肺病的单一疗法：英国的观点
4. An Automated Therapy Chair for Patients having Chronic Obstructive Pulmonary Disease (COPD) [C] . Md. Faizul Islam Chowdhury, S. M. Lutful Kabir, Sheikh Md. Rashedul Hasan IEEE International Conference on Biomedical Engineering, Computer and Information Technology for Health . 2019

机译：慢性阻塞性肺疾病（COPD）患者的自动治疗椅
5. Providing ethical care: Cardiopulmonary Resuscitation (CPR) for Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Patients with End Stage Lung Disease (ESLD). [D] . Young, Jeanne. 2010

机译：提供伦理护理：心肺复苏术（CPR）用于终末期肺病（ESLD）患者的慢性阻塞性肺疾病（COPD）加重。
6. Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective [O] . Dhvani Shah, Maurice Driessen, Nancy Risebrough, 2018

机译：乌克地林与噻托溴铵和格隆铵相比作为慢性阻塞性肺疾病单一疗法的成本效益：英国的观点
7. Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK [O] . 2015

机译：在英国有症状的慢性阻塞性肺疾病患者中，梅克立铵/维兰特罗联合治疗与噻托溴铵单药治疗相比具有成本效益
8. Outcomes Associated With Tiotropium Use in Chronic Obstructive Pulmonary Disease Patients. Effective Health Care Research Reports, Number 15 [R] . Pham, T. A., Wilke, C., Joo, M., 2009

机译：噻托溴铵用于慢性阻塞性肺疾病患者的结果。有效的医疗保健研究报告，第15号

Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅